Measuring P2X4 Receptors in Blood as a Test for ALS

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with probable or confirmed ALS (amyotrophic lateral sclerosis). Healthy volunteers can also join. It tests P2X4 on blood cells as a marker of ALS.

Age

18 years or older

Sex

All sexes can join.

Disease stage

For the ALS group: probable or confirmed ALS according to the El Escorial criteria.

Earlier treatment

People on immunosuppressive or corticosteroid treatment cannot join.

Biomarker or test result

P2X4 receptors on blood monocytes are measured from a blood sample.

Main reasons for not taking part

• Immunosuppressive or corticosteroid treatment
• Taking part in a research study with an experimental treatment
• Under guardianship, curatorship or legal protection
• Healthy volunteers who are a close relative of a patient (sibling, child, parent)

The registry criteria, word for word

What the trial wants to find out

Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease and is characterized by the degeneration of motor neurons leading to progressive paralysis and death within 3 to 5 years after diagnosis. To date, no key mechanism had been identified. Our associated laboratory has identified the P2X4 purinergic pathway that appears to be involved in the pathogenesis of ALS. Our goal is to verify these results at the human level in order to have a proof of concept of P2X4's role as a biomarker of the disease.

The 2 groups in the trial

• ALS patientTreatment being tested

  During the inclusion visit on D0, which will take place during a consultation or a hospitalization scheduled as part of the standard of care, patients will be informed about the protocol and their informed consent will be obtained. A neurological clinical examination will be performed, the ALSFRS-R score will be evaluated, as well as respiratory functional explorations and a standard biology assessment. As part of the research, an additional blood sample will be taken. For ALS patients, a follow-up visit will be performed at 6 months as part of their follow-up consultation at the ALS center. The same examinations as on D0 will be done.

  Treatment: P2X4 receptors in blood samples

• Standard : healthy subjectsOther group

  During the inclusion visit on D0, which will take place during a consultation or a hospitalization scheduled as part of the standard of care. A neurological clinical examination will be performed, the ALSFRS-R score will be evaluated, as well as respiratory functional explorations and a standard biology assessment. As part of the research, an additional blood sample will be taken. For healthy subjects, a follow-up visit will be performed at 6 months. The same examinations as on D0 will be done.

  Treatment: P2X4 receptors in blood samples